HydroxyTyrosol / ROS Cancer Research Results

HT, HydroxyTyrosol: Click to Expand ⟱

Features:

Hydroxytyrosol (HT; 3,4-dihydroxyphenylethanol) = phenolic compound from extra-virgin olive oil (EVOO) and olives; also formed from oleuropein metabolism. Small, water-soluble catechol with high antioxidant capacity.
Primary mechanisms (conceptual rank):
1) Direct ROS scavenging + lipid peroxidation inhibition (membrane protection).
2) NRF2 activation → endogenous antioxidant enzymes (HO-1, NQO1, GCLC).
3) Anti-inflammatory modulation (↓ NF-κB, ↓ COX-2, ↓ iNOS).
4) Mitochondrial protection / biogenesis support (model-dependent; PGC-1α linkage reported).
5) Anti-proliferative / pro-apoptotic signaling in cancer (dose- and model-dependent).
PK / bioavailability: well absorbed; rapid phase II metabolism (glucuronide/sulfate conjugates); short plasma half-life; free aglycone concentrations modest vs many in-vitro studies.
In-vitro vs systemic exposure: many cell studies use ≥10–100 µM; typical dietary/EVOO intake yields lower transient plasma levels (conjugated forms predominate).
Clinical evidence status: strongest data in cardiometabolic/vascular endpoints; oncology evidence largely preclinical; neuroprotection mechanistically plausible with limited RCT data.

Hydroxytyrosol is mostly only available from olive oil and leaves, but is available as a common supplement.
Hydroxytyrosol & oleuropein show the most consistent direct anti-CSC activity in multiple models (breast, colon, prostate).

Hydroxytyrosol is potent against CSC phenotypes.

Mechanisms:
-Blocks EMT, reducing transition into CSC-like states
-Inhibits Notch signaling
-Reduces CD44+ / CD24– CSC markers
-Inhibits hypoxia-driven stemness (HIF-1α suppression)

Hydroxytyrosol is especially active in:
-Breast CSCs
-Melanoma CSC-like cells
-Gastric CSC models

Hydroxytyrosol (HT) — a naturally occurring small phenolic alcohol and catechol-type polyphenol, chemically 2-(3,4-dihydroxyphenyl)ethanol (3,4-dihydroxyphenylethanol; DOPET), found in olives, extra-virgin olive oil and olive-derived extracts and also generated from oleuropein metabolism. It is classified as a dietary polyphenol / nutraceutical bioactive rather than an approved anticancer drug. HT is strongly redox-active, but its biological behavior is context-dependent: antioxidant and cytoprotective effects predominate at nutritional exposures and in normal tissues, whereas substantially higher concentrations can produce pro-oxidant stress and cancer-cell death. Oral HT is available in olive-derived supplements and as purified hydroxytyrosol.

Primary mechanisms (ranked):

Induction of cancer-cell apoptosis and cell-cycle arrest through modulation of BAX/BCL-2, caspases, p21/p27 and cyclin/CDK signaling.
Suppression of oncogenic PI3K/AKT, STAT3 and NF-κB signaling in multiple cancer models.
Suppression of tumor stemness, EMT and metastatic signaling through Wnt/β-catenin, TGF-β, EMT transcription factors and associated CSC phenotypes.
Redox modulation with preferential ROS elevation at higher anticancer concentrations; HT can shift from antioxidant to pro-oxidant behavior depending on concentration and cellular redox state.
EGFR downregulation through receptor ubiquitination and enhanced lysosomal/proteasomal degradation in colorectal cancer models.
Ferroptosis induction in some colorectal cancer models through ↓ NRF2/NQO1, ↓ SLC7A11/GPX4/GSH, ↑ iron, ↑ ROS and ↑ lipid peroxidation; this is highly context- and concentration-dependent.
Suppression of migration, invasion and angiogenic signaling, including MMPs, HIF-1α and VEGF in selected models.
NRF2-mediated antioxidant and cytoprotective signaling in non-malignant systems; this mechanism is secondary and can oppose ferroptotic or ROS-dependent anticancer strategies.

Bioavailability / PK relevance: HT is absorbed after oral administration but undergoes rapid and extensive intestinal and hepatic metabolism, particularly sulfation, glucuronidation, methylation and oxidation. Circulating free hydroxytyrosol is therefore low and transient, while conjugated metabolites predominate. The food or pharmaceutical matrix materially affects exposure; lipid-based matrices such as extra-virgin olive oil can increase apparent bioavailability. Human studies using approximately 5–45 mg oral HT demonstrate measurable systemic exposure and generally good short-term tolerability.

In-vitro vs systemic exposure relevance: A major translational limitation is the concentration gap. Many anticancer experiments use approximately 25–200 µM HT, and some older cancer models require several hundred µM for substantial growth inhibition. These concentrations are far above measured free-HT plasma concentrations after ordinary dietary or supplement dosing. Consequently, direct cytotoxic, ferroptotic and CSC-suppressive mechanisms demonstrated at high in-vitro concentrations should not be assumed to occur systemically after standard oral supplementation.

Clinical evidence status: Small human studies and randomized trials support systemic antioxidant, anti-inflammatory and cardiometabolic effects of oral HT, and a small 12-month study has investigated 25 mg/day HT in women at increased breast-cancer risk. There is currently no established therapeutic RCT evidence demonstrating treatment of an existing human cancer by hydroxytyrosol, and it is not an approved cancer therapy. Oncology evidence remains predominantly cell-culture and animal/xenograft evidence; clinical use should therefore be classified as investigational / dietary adjunct rather than anticancer treatment.

Hydroxytyrosol Cancer Mechanisms

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Apoptosis and cell-cycle control	↑ apoptosis; ↑ BAX:BCL-2; ↑ caspases; ↑ p21/p27; ↓ cyclin D1/E; ↓ CDK2/4	↔ / substantially less cytotoxicity (model-dependent)	R–G	Growth arrest and programmed cell death	One of the most consistently reproduced anticancer phenotypes; cancer-selective effects have been reported in prostate and colon models, although usually at concentrations above typical systemic nutritional exposure.
2	PI3K AKT STAT3 signaling	↓ PI3K; ↓ p-AKT; ↓ STAT3 (model-dependent)	↔ / context-dependent	R–G	Reduced survival and proliferation signaling	Observed in prostate, hematological, melanoma and other cancer models. Direction can differ under ROS-dependent stress, so AKT modulation is not universal.
3	Wnt β-catenin TGF-β and cancer stemness	↓ Wnt/β-catenin; ↓ TGF-β; ↓ EMT; ↓ CSC phenotype	↔ / context-dependent	G	Reduced stemness, invasion and metastatic phenotype	Particularly relevant to triple-negative breast-cancer models. Evidence remains preclinical and generally requires direct cellular exposure substantially above circulating free HT after dietary intake.
4	NF-κB inflammatory survival signaling	↓ NF-κB; ↓ nuclear p65 (model-dependent)	↓ inflammatory NF-κB signaling	R–G	Anti-inflammatory and anti-survival signaling	Can contribute to inhibition of proliferation and inflammatory tumor signaling while also providing anti-inflammatory effects in non-malignant cells.
5	EGFR receptor turnover	↓ EGFR	Not well characterized	R–G	Reduced proliferative receptor signaling	HT can promote Cbl-associated EGFR ubiquitination followed by lysosomal and proteasomal degradation in colorectal cancer models.
6	Pro-oxidant ROS stress	↑ ROS (high concentration only)	↓ ROS at nutritional or protective exposure	P–R	Oxidative-stress-mediated tumor-cell killing	Important dual behavior: HT is normally considered an antioxidant, but high exposure can increase ROS in colon cancer, melanoma and other malignant cells and contribute to apoptosis or ferroptosis.
7	Ferroptosis and System Xc GPX4	↑ ferroptosis; ↓ SLC7A11; ↓ GPX4; ↓ GSH; ↑ iron; ↑ lipid peroxidation (high concentration only)	↓ lipid oxidation under antioxidant conditions	R–G	Iron-dependent oxidative cell death	Demonstrated in HCT116 and SW480 colorectal cancer cells. This conflicts with treating HT as an intrinsically anti-ferroptotic antioxidant; direction is strongly dependent on tumor type and exposure.
8	NRF2 NQO1 redox defense	↓ in ferroptosis-sensitive colorectal models; ↑ or ↔ in other contexts	↑ (context-dependent)	R–G	Context-dependent control of endogenous antioxidant defenses	NRF2 should not be assigned one universal direction for HT. Activation is frequently reported in protective non-cancer models, whereas HT suppressed NRF2/NQO1 during colorectal-cancer ferroptosis. Human HT administration has not consistently demonstrated NRF2-dependent Phase II enzyme induction.
9	Mitochondrial dysfunction and membrane potential	↓ mitochondrial membrane potential (high concentration only)	↑ mitochondrial protection (context-dependent)	R	Facilitates stress-induced cancer-cell death	Another example of differential redox biology: high anticancer concentrations can disrupt mitochondrial function, while nutritional exposure can protect mitochondria in non-malignant tissues.
10	Migration invasion and angiogenic signaling	↓ MMP2/MMP9; ↓ HIF-1α; ↓ VEGF; ↓ migration/invasion (model-dependent)	↔ / context-dependent	G	Reduced metastatic and angiogenic phenotype	Supported by several preclinical systems but substantially less clinically established than apoptosis and growth-signaling effects.
11	Clinical Translation Constraint	—	—	—	Systemic exposure limits direct anticancer translation	Rapid Phase II metabolism and low circulating free HT mean that many 25–200 µM or higher experimental exposures are unlikely to be reproduced by ordinary oral supplementation. No established therapeutic cancer efficacy in humans.

TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr

Hydroxytyrosol (HT) — Cancer Stemness / EMT Axis (Addendum)

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	EMT (Epithelial–Mesenchymal Transition)	↓ (model-/dose-dependent)	↔	R→G	Reduces EMT-associated transcription (e.g., Snail, Twist)	Reported attenuation of mesenchymal phenotype; relevance strongest in breast and melanoma models; mostly in-vitro.
2	CSC markers (CD44⁺/CD24^–)	↓ (model-dependent)	↔	G	Reduces stemness-associated phenotype	Observed reduction in CSC-like populations in breast cancer models; requires supra-physiologic exposure in many studies.
3	Notch signaling	↓ (model-dependent)	↔	R→G	Stemness pathway inhibition	Downregulation of Notch pathway components reported; central to CSC maintenance; not universally replicated across tumor types.
4	HIF-1α / hypoxia-driven stemness	↓ (preclinical)	↔	R→G	Suppresses hypoxia adaptation	Reduced HIF-1α signaling may attenuate hypoxia-induced CSC traits; data strongest in gastric and breast models.
5	Tumor-type specificity	Breast, Melanoma, Gastric (preclinical)	—	—	CSC-like cell sensitivity	Evidence largely limited to cell-line and xenograft systems; translational dosing gap remains significant.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr

Alzheimer's disease relevance: Hydroxytyrosol has credible preclinical neuroprotective activity, particularly through reduction of oxidative stress and neuroinflammation, preservation of mitochondrial function and modulation of proteostasis/autophagy. Effects on amyloid pathology are inconsistent across animal models: some studies report reduced Aβ burden whereas others report cognitive and mitochondrial improvement without altered APP processing or Aβ accumulation. Human evidence specific to Alzheimer’s disease remains insufficient; cognitive studies of HT-rich olive preparations should not be interpreted as demonstrating treatment of AD.

Primary mechanisms (ranked):

Reduction of neuronal oxidative stress and lipid/protein oxidation.
Suppression of NF-κB-associated neuroinflammatory signaling.
Preservation of mitochondrial function and endogenous antioxidant defenses.
Enhancement of autophagy/proteostasis in selected AD models.
Reduction of Aβ toxicity and, in some models, Aβ plaque burden; effects on amyloid processing are inconsistent.
NRF2/SKN-1 antioxidant-response activation in experimental systems.

Clinical evidence status: Preclinical animal and cellular evidence with limited indirect human cognitive evidence. There is no convincing clinical evidence that isolated hydroxytyrosol prevents, slows or treats established Alzheimer’s disease.

Hydroxytyrosol Alzheimer Mechanisms

Rank	Pathway / Axis	Modulation	TSF	Primary Effect	Notes / Interpretation
1	Oxidative stress and lipid oxidation	↓ ROS; ↓ oxidative damage	P–R	Neuronal protection	Among the most consistent HT effects across neurodegenerative experimental systems.
2	Neuroinflammation and NF-κB	↓ NF-κB; ↓ inflammatory signaling	R–G	Reduced neuronal and glial inflammatory stress	HT attenuates Aβ-associated NF-κB activation in cellular systems and reduces inflammatory markers in animal models.
3	Mitochondrial integrity	↑	R–G	Improved bioenergetic resilience	Animal evidence supports reduced mitochondrial oxidative injury and improved mitochondrial function.
4	Autophagy and proteostasis	↑ (model-dependent)	G	Clearance of damaged or aggregation-prone proteins	Autophagy induction has accompanied cognitive improvement and reduced neuropathology in some transgenic AD models.
5	Amyloid β toxicity and deposition	↓ (model-dependent)	G	Reduced amyloid-associated neurotoxicity	Some models show reduced Aβ42 or plaque burden, whereas APP/PS1 experiments have reported neurological benefit without reduced Aβ accumulation. Therefore this should not be presented as a universal HT mechanism.
6	NRF2 antioxidant response	↑ (model-dependent)	R–G	Enhanced cellular stress resistance	Supported strongly by experimental models, but direct NRF2/Phase II activation after oral HT has not been convincingly demonstrated in humans.
7	Clinical Translation Constraint	—	—	Insufficient human AD evidence	Human cognitive studies involve olive-derived preparations or non-AD populations; isolated HT has not demonstrated disease-modifying efficacy in Alzheimer’s disease.

TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr

ROS, Reactive Oxygen Species: Click to Expand ⟱

Source: HalifaxProj (inhibit)

Type:

Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)
ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
• Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
• HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
• SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
• AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
• mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
• HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
• Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy

ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination


Item  ROS↑  NRF2  Condition  Mechanism Class  Remarks  

ROS">Piperlongumine
+++  ↓  [D][T]  ROS-dominant
Selective <span class="wphighlight">ROS</span> stressor, Prevents compensatory upregulation of NRF2, ie GSH↓



ROS">Shikonin
+++ ↓/± [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + glycolysis + GPX4 inhibition



ROS">Vitamin K3 (menadione)
+++ ↓ [D] ROS-dominant
Quinone redox cycler; toxicity limits use



ROS">Copper (ionic / nano)
+++ ↓ [Fe][F] ROS-dominant
Fenton-type redox chemistry



ROS">Sodium Selenite
+++ ↓ [D] ROS-dominant
Pro-oxidant, depletes GSH



ROS">Juglone
+++ ↓ [D] ROS-dominant
Strong quinone <span class="wphighlight">ROS</span> chemistry



ROS">Auranofin
+++ ↓ [D] ROS-dominant
TrxR inhibition → redox collapse



ROS">Photodynamic Therapy (PDT)
+++ 0 [L][O₂] ROS-dominant
Singlet oxygen is core cytotoxic mechanism



ROS">Radiotherapy / Radiation
+++ 0 [O₂] ROS-dominant
DNA damage largely via <span class="wphighlight">ROS</span>



ROS">Doxorubicin
+++ ↓ [D] ROS-dominant
Chemo; redox cycling + mitochondrial <span class="wphighlight">ROS</span>



ROS">Cisplatin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> contributes to DNA/protein damage



ROS">Salinomycin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated CSC toxicity



ROS">Artemisinin / DHA
++ ↓ [Fe][T] ROS-dominant
Iron-activated radical generation



ROS">Sulfasalazine
++ ↓ [C][T] ROS-dominant
Ferroptosis; xCT inhibition → lipid <span class="wphighlight">ROS</span>



ROS">FMD / fasting
++ ↓ [M][C][O₂] ROS-dominant
Metabolic stress → mitochondrial <span class="wphighlight">ROS</span>



ROS">Vitamin C (pharmacologic)
++ ↓ [Fe][D] ROS-dominant
Extracellular H₂O₂ at high dose



ROS">Silver nanoparticles
++ ± [F][D] ROS-dominant
<span class="wphighlight">ROS</span> common; selectivity unreliable



ROS">Gambogic acid
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Parthenolide
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + NF-κB suppression



ROS">Plumbagin
++ ↓ [D] ROS-dominant
Quinone <span class="wphighlight">ROS</span> driver



ROS">Allicin
++ ↓ [D] ROS-dominant
Thiol-reactive oxidative stress



ROS">Ashwagandha (Withaferin A)
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Berberine
++ ↓ [D][M] ROS-dominant
Mitochondrial <span class="wphighlight">ROS</span> induction



ROS">PEITC
++ ↓ [D][C] ROS-dominant
GSH depletion + <span class="wphighlight">ROS</span>



ROS">Methionine restriction
+ ↓ [M][C][T] ROS-secondary
Redox vulnerability increased; <span class="wphighlight">ROS</span> indirect



ROS">DCA
+ ± [M][T] ROS-secondary
<span class="wphighlight">ROS</span> via forced OXPHOS



ROS">Capsaicin
+ ± [D][T] ROS-secondary
Ca²⁺ stress → <span class="wphighlight">ROS</span>



ROS">Galloflavin
+ 0 [D] ROS-secondary
<span class="wphighlight">ROS</span> not primary driver



ROS">Piperine
+ ± [D][F] ROS-secondary
Weak <span class="wphighlight">ROS</span> induction



ROS">Propyl gallate
+ ↓ [D] ROS-secondary
Pro-oxidant at high dose



ROS">Scoulerine
+ ? [D][T] ROS-secondary
Sparse <span class="wphighlight">ROS</span> data



ROS">Thymoquinone
± ± [D][T] Dual redox
Antioxidant ↔ pro-oxidant switch



ROS">Emodin
± ± [D][T] Dual redox
Not cancer-exclusive



ROS">Alpha-lipoic acid (ALA)
± ↑ [D][M] NRF2-dominant
Antioxidant at low dose



ROS">Curcumin
± ↑/↓ [D][F] NRF2-dominant
Hormetic redox behavior



ROS">EGCG
± ↑/↓ [D][O₂] NRF2-dominant
Auto-oxidation artifacts common



ROS">Quercetin
± ↑/↓ [D][Fe] NRF2-dominant
GSH-dependent cycling



ROS">Resveratrol
± ↑ [D][M] NRF2-dominant
<span class="wphighlight">ROS</span> only at high dose



ROS">Sulforaphane
± ↑↑ [D] NRF2-dominant
Strong NRF2 activator



ROS">Lycopene
0 ↑ — Antioxidant
Consistently antioxidant



ROS">Rosmarinic acid
0 ↑ — Antioxidant
Primarily antioxidant



ROS">Citrate
0 0 — Neutral
Metabolic; not a <span class="wphighlight">ROS</span> agent

Scientific Papers found: Click to Expand⟱

7542-

HT,

Hydroxytyrosol Induces Apoptosis and Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells

in-vitro,

Pca,

LNCaP

in-vitro,

Pca,

C4-2B

in-vitro,

Nor,

RWPE-1

TumCP↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, CDK2↓, CDK4↓, Apoptosis↑, Casp↑, cl‑PARP↑, Bax:Bcl2↑, tumCV↓, Akt↓, STAT3↓, NF-kB↓, AR↓, ROS↑, mtDam↑, BioAv↓, toxicity↓, eff↑,

7540-

HT,

Discovery of hydroxytyrosol as thioredoxin reductase 1 inhibitor to induce apoptosis and G1/S cell cycle arrest in human colorectal cancer cells via ROS generation

in-vitro,

CRC,

HCT8

in-vitro,

CRC,

HCT116

TrxR1↑, ROS↑, TumCP↓, Apoptosis↑, TumCCA↑, Dose↝, eff↓,

7538-

HT,

An Olive-Derived Extract 20% Rich in Hydroxytyrosol Prevents β-Amyloid Aggregation and Oxidative Stress, Two Features of Alzheimer Disease, via SKN-1/NRF2 and HSP-16.2 in Caenorhabditis elegans

in-vivo,

AD,

*ROS↓, *Aβ↓,

7537-

HT,

Hydroxytyrosol Alleviated Hypoxia-Mediated PC12 Cell Damage through Activating PI3K/AKT/mTOR-HIF-1 α Signaling

in-vitro,

Nor,

PC12

*ROS↓, *mtDam↓, *PI3K↑, *Akt↑, *mTOR↑, *Hif1a↑,

7528-

HT,

Involvement of the PI3K/AKT Intracellular Signaling Pathway in the AntiCancer Activity of Hydroxytyrosol, a Polyphenol from Olea europaea, in Hematological Cells and Implication of HSP60 Levels in Its Anti-Inflammatory Activity

NA,

Jurkat

27.3 µg·mL−1

NA,

HL-60

109.8 µg·mL−1

NA,

RAW264.7

45.7 µg·mL−1

*antiOx↑, *Inflam↓, *AntiBio↑, *cardioP↑, AntiCan↑, TumCCA↑, PI3K↓, MAPK↑, ROS↑, Apoptosis↑, Casp9↑, Bcl-2↓, p‑P53↓,

4635-

HT,

Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention in Women at High Risk of Cancer

Trial,

BC,

Twenty-five milligrams per day oral dose of HT was given for 12 months

*Wnt↓, *NOTCH↓, *ROS↓, TumCP↓, CSCs↓,

4637-

HT,

Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells

in-vitro,

Nor,

RWPE-1

52.20 ± 4.19

in-vitro,

Pca,

LNCaP

41.17 ± 2.79

in-vitro,

Pca,

22Rv1

9.32 ± 0.50

in-vitro,

Pca,

PC3

28.88 ± 2.25

selectivity↑, TumCMig↓, p‑Akt↓, ROS↑, CSCs↓, CD44↓, TumCP↓,

4638-

HT,

Hydroxytyrosol induces apoptosis in human colon cancer cells through ROS generation

in-vitro,

CRC,

DLD1

NA,

selectivity↑, ROS↑, Akt↑, FOXO3↓, Apoptosis↑,

4639-

HT,

Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells

in-vitro,

Pca,

LNCaP

in-vitro,

Pca,

C4-2B

TumCP↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, P21↑, p27/CDKN1B↑, Apoptosis↑, Casp↑, cl‑PARP↑, Bax:Bcl2↑, p‑Akt↓, p‑STAT3↓, NF-kB↓, AR↓, ROS↑, *BioAv↓, *toxicity∅,

4641-

HT,

Hydroxytyrosol induced ferroptosis through Nrf2 signaling pathway in colorectal cancer cells

in-vitro,

CRC,

HCT116

in-vitro,

CRC,

SW48

Ferroptosis↑, Iron↑, lipid-P↑, ROS↑, GSH↓, MMP↓, GPx4↓, TLR1↑, eff↓, NRF2↓, ROS↑,

4644-

HT,

The Hydroxytyrosol Induces the Death for Apoptosis of Human Melanoma Cells

in-vitro,

Melanoma,

tumCV↓, Apoptosis↑, P53↑, γH2AX↑, Akt↓, ROS↑, DNAdam↑,

4643-

OLE,

HT,

Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine

Review,

Var,

TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP/DDIT3↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27/CDKN1B↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,

Showing Research Papers: 1 to 12 of 12

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 12

Pathway results for Effect on Cancer / Diseased Cells:

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1, toxicity↓, 1,
Total Targets: 75

Pathway results for Effect on Normal Cells:

NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1, Catalase↑, 1, GSH↑, 1, MDA↓, 1, NRF2↑, 1, ROS↓, 4, SOD↑, 1,

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↓, 1,

Cell Death(tgid=5) ⓘ

Akt↑, 1,

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

mTOR↑, 1, NOTCH↓, 1, PI3K↑, 1, Wnt↓, 1,

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↑, 1,

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 2,

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1, chemoP↑, 1, toxicity∅, 1,
Total Targets: 21

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species

12 HydroxyTyrosol
1 Oleuropein

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:376  Target#:275  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

HydroxyTyrosol / ROS Cancer Research Results

Hydroxytyrosol Cancer Mechanisms

Hydroxytyrosol (HT) — Cancer Stemness / EMT Axis (Addendum)

Hydroxytyrosol Alzheimer Mechanisms

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

Transcription & Epigenetics(tgid=7) ⓘ

Protein Folding & ER Stress(tgid=8) ⓘ

DNA Damage & Repair(tgid=10) ⓘ

Cell Cycle & Senescence(tgid=11) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Hormonal & Nuclear Receptors(tgid=20) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Pathway results for Effect on Normal Cells:

NA, unassigned(tgid=0) ⓘ

Redox & Oxidative Stress(tgid=1) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Cell Death(tgid=5) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Protein Aggregation(tgid=19) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Functional Outcomes(tgid=23) ⓘ

Home Page